In 2025, the Consortium for Personalised Prostate Cancer Prevention was established to bring a new model of personalised prostate cancer prevention to men across the United Kingdom. This initiative allows men to access individualised prostate cancer risk assessments and targeted early detection services through leading experts and clinical partners.
Personalised Prostate Cancer Prevention is a telemedicine-based clinical service, offered in collaboration with leading UK and international prostate cancer specialists and coordinated by Antegenes Ltd.
The service is supported by top clinicians and researchers in the field of urology, medical genetics, and cancer prevention. It is based on the latest scientific evidence and aligns with international guidelines from the European Association of Urology (EAU).
The service is organised and coordinated by Antegenes Ltd, UK. Antegenes is an ISO 13485-certified European provider of personalised cancer prevention services.
Polygenic risk score analysis is performed using the CE-IVD certified AntePC test, which is registered in the UK MHRA Registry (GMDN code: 63668) and conducted in Antegenes’ certified medical genetics laboratory.
Through this partnership, men aged 40–70 can access a clinically validated, evidence-based service that supports smarter, earlier, and more targeted prostate cancer screening.
